Monograph Title | Section | Source Publication | Page Number Sort descending | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
AMOXICILLIN FOR INJECTABLE SUSPENSION | Identification | USPNF Online | Online | 27-Oct-2023 | 1-Nov-2023 | NA | NA | Change Prepare a test solution containing the equivalent of 4 mg of amoxicillin per mL by adding 0.1 N hydrochloric acid to Amoxicillin for Injectable Suspension. Allow the solution to stand for 5 minutes before use: the solution responds to the Identification… Read More |
IODIXANOL INJECTION | IMPURITIES | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | In Organic Impurities, Procedure 2/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hy… Read More |
GANODERMA LUCIDUM FRUITING BODY | COMPOSITION/Content of Triterpenoic Acids | Revision Bulletin (Official August 01, 2014) | Online | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Standard solution A: Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in Analysis: Change rS = peak area of ganoderic acid in Standard solution A to: rS… Read More |
ALMOTRIPTAN MALATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Interim Revision Announcement (Official May 01, 2017) | Online | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine N-oxide. C17H25N3O3S 351.46 to: 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine N… Read More |
RIVASTIGMINE TARTRATE | IMPURITIES | USPNF Online | Online | 26-Apr-2024 | 1-May-2024 | NA | NA | In Organic Impurities/Procedure 1/Impurity Table 1/footnote d: Change 3-Nitrophenyl ethyl(methyl)carbamate. to: 4-Nitrophenyl ethyl(methyl)carbamate. |
MINOXIDIL TABLETS | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | In Analysis: Change Result = (rU/rS) × (CU/CS) × 100 to: Result = (rU/rS) × (CS/CU) × 100 |
CETIRIZINE HYDROCHLORIDE | IMPURITIES/Residue on Ignition 〈281〉 | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | Delete Sample: 1 g |
ISOPROTERENOL HYDROCHLORIDE INJECTION | Color and clarity | USPNF 2021 ISSUE 1 | Online | 19-Nov-2021 | 1-Dec-2021 | NA | NA | Change Using the Injection as the Test solution, proceed as directed for Color and clarity under Isoproterenol Inhalation Solution. to: Standard solution—Transfer 2.0 mL of 0.100 N iodine VS to a 500-mL volumetric flask,… Read More |
FULVESTRANT | CHEMICAL INFORMATION | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | Change 606.77 to: 606.78 |
DIMENHYDRINATE TABLETS | OTHER COMPONENTS/8-Chlorotheophylline | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | In Analysis: Change CU = nominal concentration of dimenhydrinate in the Sample solution (mg/mL) to: CU = determined concentration of dimenhydrinate in the Sample solution, as obtained in the Assay… Read More |
BACLOFEN INJECTION | SPECIFIC TESTS | USPNF Online | Online | 29-Jul-2022 | 1-Aug-2022 | NA | NA | Change • Osmolality and Osmolarity 〈785〉, Osmolality: 270–320 mOsm/kg to: • Osmolality and Osmolarity 〈785〉 Osmolality: 270–320 mOsm/kg |
TETRACYCLINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/Labeling | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | Change Where tetracycline hydrochloride must be sterile or subjected to further processing during the preparation of injectable dosage forms to ensure acceptable levels of bacterial endotoxins, it is so labeled. to: Where Tetracycline Hydrochloride must be… Read More |
MESO-ZEAXANTHIN | CHEMICAL INFORMATION | USPNF Online | Online | 27-Jan-2023 | 1-Jun-2023 | NA | NA | Change (3R,3′S-meso)-Zeaxanthin to: (3R,3′S)-Zeaxanthin |
PRAZOSIN HYDROCHLORIDE CAPSULES | ASSAY/Procedure | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | In Analysis: Change CS = concentration of USP Prazosin Hydrochloride RS in the Standard solution (µg/mL) CU = nominal concentration of prazosin in the Sample solution (µg/mL) Mr1… Read More |
DIGOXIN TABLETS | ASSAY/Procedure | USPNF Online | Online | 30-Jun-2023 | 1-Jul-2023 | NA | NA | In Chromatographic system: Change Column: 4.2-mm × 25-cm; 5-μm packing L1 to: Column: 4.6-mm × 25-cm; 5-µm packing L1 |
CRANBERRY FRUIT DRY JUICE | COMPOSITION | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Content of Proanthocyanidins/Standard stock solution: Change USP Procyanidin A2 RS to: USP Procyanidin A2 RS AND In Content of Proanthocyanidins/Analysis: Change Use the absorbance recorded for Standard… Read More |
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In USP Reference Standards 〈11〉/USP Dihydrodutasteride RS: Change N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide. to: N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androstane-17β-carboxamide. |
Olanzapine Tablets | IMPURITIES/Organic Impurities | Revision Bulletin (Official July 01, 2012) | Online | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 11 of Analysis: Change CU = concentration of olanzapine in the Sample solution (mg/mL) to: CU = nominal concentration of olanzapine in the Sample solution (mg/mL) |
TRIAMTERENE | IMPURITIES/Organic Impurities | First Supplement to USP41–NF36 | Online | 28-Sep-2018 | 1-Oct-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | This erratum applies to the new USP-NF ONLINE platform only. Line 1 of Standard stock solution 2: Change 0.1 mg/mL of in Diluent. to: 0.1 mg/mL of USP Triamterene Related Compound A RS in Diluent. AND Line 1 of … Read More |
DEXMEDETOMIDINE HYDROCHLORIDE | CHEMICAL INFORMATION | USP41–NF36 | Online | 22-Feb-2019 | 1-Mar-2019 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. See https://www.uspnf.com/sites/default/files/usp_pdf/EN/february_2019_errata_image1.pdf for correction |
<661> PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION | POLYETHYLENE TEREPHTHALATE BOTTLES AND POLYETHYLENE TEREPHTHALATE G CONTAINERS | First Supplement to USP43–NF38 | Online | 30-Oct-2020 | 1-Nov-2020 | NA | NA | In Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Extracting media: Change 50 percent alcohol: Dilute 125 mL of alcohol with water to 238 mL, and mix. 25 percent alcohol: Dilute 125 mL of 50 percent alcohol… Read More |
<1092> THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION | 1. PRELIMINARY ASSESSMENT | Second Supplement to USP43–NF38 | Online | 20-Nov-2020 | 1-Dec-2020 | NA | NA | In paragraph 4 of 1.4 Choosing an apparatus: Change peak vessels to: apex vessels |
CARVEDILOL | IMPURITIES/Organic Impurities, Procedure 2 | USP43–NF38 | Online | 18-Dec-2020 | 1-Jan-2021 | NA | NA | In Table 3/footnote b: Change 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(6,7,8,9-tetrahydro-5H-carbazol-4-yloxy)propan-2-ol. to: 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1H-carbazol-5-yloxy)propan-2-ol. |
MIRTAZAPINE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | Online | 26-Mar-2021 | 1-Apr-2021 | NA | NA | In USP Mirtazapine Resolution Mixture RS: Change Impurity D: 1,2,3,4,10,14b-Hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine. to: Impurity D: [Note–This impurity may be available either as the free base form or as the hydrochloride salt… Read More |
DACTINOMYCIN | CHEMICAL INFORMATION | USP43–NF38 | Online | 25-Jun-2021 | 1-Jul-2021 | NA | NA | Please see the updated chemical structure at online.uspnf.com |
QUETIAPINE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/System Suitability | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In Resolution: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks |
ONDANSETRON | USP Reference standards <11> | USPNF 2021 ISSUE 1 | Online | 31-Dec-2021 | 1-Jan-2022 | NA | NA | Change USP Ondansetron RS USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one. USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one. to: USP… Read More |
ONDANSETRON ORAL SOLUTION | USP Reference standards <11> | USPNF Online | Online | 25-Mar-2022 | 1-Apr-2022 | NA | NA | Change USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one. USP… Read More |
IVERMECTIN | CHEMICAL INFORMATION | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | Change C48H74O14(Component H2B1a) 875.09 C47H72O14(Component H2B1b) 861.07 Component H2B1a: Avermectin… Read More |
POTASSIUM GLUCONATE | IMPURITIES/Reducing Substances | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | NA | In Titrimetric system: Change Titrant: Iodine Back-titrant: Sodium thiosulfate to: Titrant: 0.1 N Iodine VS Back-titrant: 0.1 N Sodium Thiosulfate VS |
CALCIUM UNDECYLENATE | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Solution A: Change 0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well. to: 0.15 N hydrochloric acid in water prepared as follows.… Read More |
POLYETHYLENE GLYCOL STANDARDS WITH MOLECULAR WEIGHTS OF 1000, 2000, 3000, 4000, AND 6000 DALTONS (G/MOL) | CHEMICAL INFORMATION | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | Change CAS RN®: 25332-68-3. to: CAS RN®: 25322-68-3. |
ACARBOSE TABLETS | IDENTIFICATION/B. | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Change The spectrum obtained from the Sample solution shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm–1. to: The spectrum obtained from the sample preparation shows IR maxima in the regions of 3500–3200… Read More |
<3> TOPICAL AND TRANSDERMAL DRUG PRODUCTS—PRODUCT QUALITY TESTS | SPECIFIC TESTS FOR TDS | USPNF Online | Online | 28-Jul-2023 | 1-Dec-2023 | NA | NA | In Release Liner Peel Test: Change The product fails the test if the mean peel force is outside the acceptable range determined during product development. to: The product fails the test if the overall mean peel force is outside the acceptable range… Read More |
VALGANCICLOVIR HYDROCHLORIDE | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Organic Impurities/Table 3/footnote c: Change 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]-2-hydroxypropyl methyl-L-valinate hydrochloride. to: 3-[(2-Amino-6-oxo-1,6-dihydropurin-9-yl)methoxy]-2-hydroxypropyl L… Read More |
ACARBOSE | IMPURITIES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In Chromatographic Purity/Analysis: Change Result = (rU/rA) × (1/F) × 100 to: Result = (rU/rA) × (1/F) |
<795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS | COMPOUNDING FACILITIES | Revision Bulletin (Official January 01, 2014) | Online | 28-Mar-2014 | 1-Apr-2014 | Second Supplement to USP37–NF32 | Second Supplement to USP37–NF32 | Line 4 of Paragraph 4: Change (see the General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity; to: (see Packaging and Storage Requirements <659>; |
MINERAL OIL | SPECIFIC TESTS/Readily Carbonizable Substances Test <271> | Second Supplement to USP37–NF32 | Online | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Acceptance criteria: Change The Sample may turn hazy, but it remains colorless, or shows a slight pink or yellow color, and the Sample does not become darker than the Standard solution. to: The oil portion of the Sample may turn hazy, but it… Read More |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | ASSAY/Procedure | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In System suitability: Add [Note—The relative retention times for oxybutynin and oxybutynin related compound A are about 1.0 and 1.6,… Read More |
TRANYLCYPROMINE SULFATE | CHEMICAL INFORMATION | USP43–NF38 | Online | 29-May-2020 | 1-Jun-2020 | NA | NA | See https://www.uspnf.com/errata/tranylcypromine-sulfate-image for correction. |
GALANTAMINE EXTENDED-RELEASE CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | First Supplement to USP43–NF38 | Online | 30-Oct-2020 | 1-Nov-2020 | NA | NA | In USP Galantamine Hydrobromide Related Compounds Mixture RS: Change Anhydrogalantamine; (4aS,8aS)-3-Methoxy-11-methyl-9,10,11,12-tetrahydro-4aH-benzo[2,3]benzofuro[4,3-cd]azepine. C17H19NO2 to: … Read More |
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS | IMPURITIES/Organic Impurities | USP43–NF38 | Online | 26-Feb-2021 | 1-Mar-2021 | NA | NA | In the first variable definition list in Analysis: Change 522.93 to: 522.94 |
AMITRIPTYLINE HYDROCHLORIDE | CHEMICAL INFORMATION | USP43–NF38 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | Change 313.86 to: 313.87 |
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 29-Oct-2021 | 1-Nov-2021 | NA | NA | In Analysis: Change rS = peak response of alfuzosin from the Sample solution to: rS = peak response of alfuzosin from the Standard solution |
ONDANSETRON INJECTION | USP Reference standards <11> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride. AND… Read More |
MUPIROCIN CREAM | Related compounds/Table 1 | USPNF Online | Online | 29-Apr-2022 | 1-May-2022 | NA | NA | In footnote 2: Change 9-{(E)-4-[(2R,3aS,6S,7S,8aRS)-2-{(1RS,2S,3S)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2H-furo[3,2-c]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to:… Read More |
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS | IMPURITIES/Limit of Homatropine Hydrobromide and Related Substances | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In Buffer: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1. |
TERAZOSIN CAPSULES | ASSAY/Procedure | USPNF Online | Online | 30-Sep-2022 | 1-Oct-2022 | NA | NA | In Hydrochloric acid solution: Change 0.1 N methanolic hydrochloric acid to: 0.01 N methanolic hydrochloric acid |
ROCURONIUM BROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | Change 609.68 to: 609.69 |
LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJECTION | Assay for lidocaine hydrochloride | USPNF Online | Online | 24-Feb-2023 | 1-Mar-2023 | NA | NA | Change Proceed with Injection as directed in the Assay for lidocaine hydrochloride under Lidocaine and Epinephrine Injection. to: Proceed with Injection as directed in the Assay for lidocaine hydrochloride under Lidocaine… Read More |